Drug-resistant tuberculosis - Revision history

Aidan: /* Management */

2025-01-02T20:01:32Z

Management

← Older revision		Revision as of 20:01, 2 January 2025
Line 28:		Line 28:
	** Group A: [[fluoroquinolones]] (except [[ciprofloxacin]]), [[bedaquiline]], [[linezolid]]		** Group A: [[fluoroquinolones]] (except [[ciprofloxacin]]), [[bedaquiline]], [[linezolid]]
	** Group B: [[clofazimine]], [[cycloserine]] (or [[terizidone]])		** Group B: [[clofazimine]], [[cycloserine]] (or [[terizidone]])
	** Group C: [[ethambutol]], [[pyrazinamide]], [[delamanid]], [[amikacin]] (or [[streptomycin]]), [[imipenem-cilastatin]] (or [[meropenem)]], [[ethionamide]], [[p-aminosalicylic acid]]		** Group C: [[ethambutol]], [[pyrazinamide]], [[delamanid]], [[amikacin]] (or [[streptomycin]]), [[imipenem-cilastatin]] (or [[meropenem-clavulanate]]), [[ethionamide]], [[p-aminosalicylic acid]]
	* For low-burden disease, can consider a 4-drug regimen		* For low-burden disease, can consider a 4-drug regimen
	* Duration		* Duration

Aidan at 17:39, 19 September 2024

2024-09-19T17:39:55Z

← Older revision		Revision as of 17:39, 19 September 2024
Line 36:		Line 36:
	=== BPaLM ===		=== BPaLM ===

	* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months<ref>Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: [~~https~~:~~//doi.org/10.1056/NEJMoa2117166 10.1056/NEJMoa2117166]. PMID~~: ~~36546625.</ref>~~ now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]		* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months[[CiteRef::nyang’wa2022a]] now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]
	* Should be avoided in CNS disease, disseminated TB, children, or pregnant patients		* Should be avoided in CNS disease, disseminated TB, children, or pregnant patients

Aidan at 01:48, 2 April 2023

2023-04-02T01:48:32Z

← Older revision		Revision as of 01:48, 2 April 2023
Line 34:		Line 34:
	** Total treatment duration between 15 and 21 months after culture conversion		** Total treatment duration between 15 and 21 months after culture conversion

	=== ~~Novel Regimens~~ ===		=== BPaLM ===

	* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months<ref>Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: [https://doi.org/10.1056/NEJMoa2117166 10.1056/NEJMoa2117166]. PMID: 36546625.</ref> now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]		* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months<ref>Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: [https://doi.org/10.1056/NEJMoa2117166 10.1056/NEJMoa2117166]. PMID: 36546625.</ref> now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]
			* Should be avoided in CNS disease, disseminated TB, children, or pregnant patients

	=== Specific Resistance Patterns ===		=== Specific Resistance Patterns ===

Aidan at 01:47, 2 April 2023

2023-04-02T01:47:50Z

← Older revision		Revision as of 01:47, 2 April 2023
Line 34:		Line 34:
	** Total treatment duration between 15 and 21 months after culture conversion		** Total treatment duration between 15 and 21 months after culture conversion

			=== Novel Regimens ===

			* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months<ref>Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: [https://doi.org/10.1056/NEJMoa2117166 10.1056/NEJMoa2117166]. PMID: 36546625.</ref> now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]

			=== Specific Resistance Patterns ===
	{\| class="wikitable"		{\| class="wikitable"
	!Resistance To		!Resistance To

Aidan at 01:39, 2 April 2023

2023-04-02T01:39:51Z

@@ Line 1: / Line 1: @@
-* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and rifampin
+* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and [[rifampin]]
-== Classification ==
+=== Classification ===
 * '''Multidrug resistant tuberculosis (MDR-TB)''': resistance to [[isoniazid]] and [[rifampicin]]
 * '''Extensively drug-resistant tuberculosis (XDR-TB)''': resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
 * '''Totally drug-resistant tuberculosis (TDR-TB)''': not well-defined
 == Management ==
 {| class="wikitable"

Aidan: /* Management */

2022-11-18T17:58:52Z

Management

← Older revision		Revision as of 17:58, 18 November 2022
Line 65:		Line 65:
	\|9 months from date FQN started		\|9 months from date FQN started
	\|}		\|}
	*

	[[Category:Tuberculosis]]		[[Category:Tuberculosis]]

Aidan: /* Management */

2022-11-18T17:58:39Z

Management

← Older revision		Revision as of 17:58, 18 November 2022
Line 16:		Line 16:
	{\| class="wikitable"		{\| class="wikitable"
	!Resistance To		!Resistance To
			!Replace With
	!Drug to Stop
	!Drug to Add
	!Regimen		!Regimen
	!Total Duration		!Total Duration
	\|-		\|-
	\|INH
	\|INH		\|INH
	\|FQN		\|FQN
Line 27:		Line 25:
	\|6 months from date FQN started		\|6 months from date FQN started
	\|-		\|-
	\|INH
	\|INH		\|INH
	\|FQN		\|FQN
Line 33:		Line 30:
	\|6 months from date FQN started		\|6 months from date FQN started
	\|-		\|-
	\|RMP
	\|RMP		\|RMP
	\|FQN		\|FQN
Line 39:		Line 35:
	\|18 months from date FQN started		\|18 months from date FQN started
	\|-		\|-
	\|RMP
	\|RMP		\|RMP
	\|None		\|None
Line 45:		Line 40:
	\|18 months from date FQN started		\|18 months from date FQN started
	\|-		\|-
	\|EMB
	\|EMB		\|EMB
	\|None		\|None
Line 51:		Line 45:
	\|6 months from start of therapy		\|6 months from start of therapy
	\|-		\|-
	\|PZA
	\|PZA		\|PZA
	\|None		\|None
Line 57:		Line 50:
	\|9 months from start of therapy		\|9 months from start of therapy
	\|-		\|-
	\|INH+EMB
	\|INH+EMB		\|INH+EMB
	\|FQN		\|FQN
Line 63:		Line 55:
	\|6 months from date FQN started		\|6 months from date FQN started
	\|-		\|-
	\|INH+PZA
	\|INH+PZA		\|INH+PZA
	\|FQN		\|FQN
Line 69:		Line 60:
	\|9 months from date FQN started		\|9 months from date FQN started
	\|-		\|-
	\|INH+EMB+PZA
	\|INH+EMB+PZA		\|INH+EMB+PZA
	\|FQN+injectable		\|FQN+injectable

Aidan: /* Management */

2022-11-18T17:58:13Z

Management

← Older revision		Revision as of 17:58, 18 November 2022
Line 13:		Line 13:
	** Other second-line agents, starting with ethionamide		** Other second-line agents, starting with ethionamide
	* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months		* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months

	*
	{\| class="wikitable"		{\| class="wikitable"
	!Resistance To		!Resistance To

Aidan at 17:58, 18 November 2022

2022-11-18T17:58:03Z

@@ Line 13: / Line 13: @@
 ** Other second-line agents, starting with ethionamide
 * Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
 [[Category:Tuberculosis]]

Aidan: Text replacement - "Category:TB" to "Category:Tuberculosis"

2020-06-01T16:56:17Z

Text replacement - "Category:TB" to "Category:Tuberculosis"

← Older revision		Revision as of 16:56, 1 June 2020
Line 14:		Line 14:
	* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months		* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months

	[[Category:TB]]		[[Category:Tuberculosis]]